

1212J

e.K

Prophylactic and remedial preparation for diseases attendant on hyperglycemia, and wholesome food

Patent Number: EP0560284
Publication date: 1993-09-15
Inventor(s): SERI KENJI (JP); SANAI KAZUKO (JP); NEGISHI SHIGENORI (JP); AKINO TOSHIRO (JP)
Applicant(s): GODO SHUSEI KK (JP)
Requested Patent: ☐ EP0560284, B1
Application Number: EP19930103763 19930309
Priority Number(s): JP19920086196 19920310; JP19920355368 19921221
IPC Classification: A61K31/70
EC Classification: A61K31/70B
Equivalents: CA2091049, DE69311932D, DE69311932T, ☐ JP6065080
Cited Documents: US4745185; WO9109604; EP0456948; JP63308001

Abstract

A prophylactic and remedial preparation for a disease attendant on hyperglycemia, a preparation for depressing the rise in blood sugar, and a wholesome food separately include, as an active ingredient, at least one component selected from the group consisting of L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose.

Data supplied from the esp@cenet database - I2

Claims

1. A prophylactic and remedial preparation for a disease attendant on hyperglycemia, comprising, as an active ingredient, at least one component selected from the group consisting of L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose.
2. The prophylactic and remedial preparation as claimed in claim 1, wherein the disease attendant on hyperglycemia is diabetes, prediabetes, obesity, hyperlipemia or arteriosclerosis.
3. A prophylactic and remedial preparation composition for a disease attendant on hyperglycemia, comprising, as an active ingredient, at least one component selected from the group consisting of L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose, and pharmaceutical additives.
4. The prophylactic and remedial preparation composition as claimed in claim 3, wherein the disease attendant on hyperglycemia is diabetes, prediabetes, obesity, hyperlipemia or arteriosclerosis.
5. A method of remedying a disease attendant on hyperglycemia, which comprises administering to a patient of the disease attendant on hyperglycemia at least one component selected from the group consisting of L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose in an effective dose.
6. The method as claimed in claim 5, wherein the disease attendant on hyperglycemia is diabetes, prediabetes, obesity, hyperlipemia or arteriosclerosis.
7. A preparation composition for depressing the rise in blood sugar due to carbohydrate ingestion, comprising, as an active ingredient, at least one component selected from the group consisting of L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose, and pharmaceutical additives.
8. A method of depressing the rise in blood sugar due to carbohydrate ingestion, which comprises administering at least one component selected from the group consisting of L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose in an effective dose.
9. A wholesome food for preventing obesity, comprising at least one component selected from the group consisting of L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose in a proportion of at least 2 wt.% of other carbohydrates than those specified herein.

Data supplied from the esp@cenet database - 12

Description

BACKGROUND OF THE INVENTION

i) Field of the Invention:

This invention relates to drugs which are intended to prevent and remedy diseases attendant on hyperglycemia after each meal, for example, diabetes, prediabetes, obesity, hyperlipemia, arteriosclerosis, etc., and wholesome foods.

ii) Description of the Background Art:

alpha -Glucosidases represented by sucrase and maltase are enzymes which bear a leading role in hydrolysis of carbohydrates in the intestine, and exert a vital influence on carbohydrate absorption. Therefore, sucrase inhibitors and maltase inhibitors are useful as preparations for depressing the rise in blood sugar after each meal (U.S. Patent No. 4,062,950, Japanese Patent Application Laid-Open No. 156945/1989).

However, most of the conventionally-known sucrase inhibitors and maltase inhibitors were secondary metabolites produced by microorganisms and were not contained in foods generally ingested by human beings. Accordingly, these substances are foreign matters to the living body, and have hence been left a fear as to the safety in the case where they are taken up from the digestive tract into the blood and reach the systemic organs. In principal organs such as the liver, heart or skeletal muscle, in which the hydrolytic metabolism of carbohydrates actively takes place, in particular, a fear has been emphatically pointed out for long-term safety.

Accordingly, there has been a demand for development of an alpha -glucosidase inhibitor which is a substance contained in foods generally ingested, and is highly safe for the living body in that it is hard to be taken up from the digestive tract, is discharged quickly if taken up, and is hence not retained in the human body.

SUMMARY OF THE INVENTION

It is an object of this invention to provide a prophylactic and remedial preparation for the above-described symptoms and a wholesome food, which can solve the above-described problems involved in the prior art and comprises, as an active ingredient, an alpha -glucosidase inhibitor having excellent physical properties and physiological functions and derived from substances occurred in nature.

The present inventors have researched and studied the alpha -glucosidase-inhibiting actions, laying stress on the sucrase-inhibiting action and maltase-inhibiting action, of various pentoses, hexoses and oligosaccharides which occur in nature, and investigated in detail their actions to depress the rise in blood sugar after carbohydrate loading by using laboratory animals.

As a result, it has been found that some pentoses and hexoses including L-arabinose have strong sucrase-inhibiting action and maltase-inhibiting action, and moreover are remarkably effective in depressing the rise in blood sugar after carbohydrate loading, leading to completion of the present invention.

In an aspect of the present invention, there is thus provided a prophylactic and remedial preparation for a disease attendant on hyperglycemia, comprising, as an active ingredient, at least one component selected from the group consisting of L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose.

In another aspect of this invention, there is also provided a prophylactic and remedial preparation

composition for a disease attendant on hyperglycemia, comprising, as an active ingredient, at least one of the above-specified monosaccharides, and pharmaceutical additives.

In a further aspect of this invention, there is also provided a method of remedying a disease attendant on hyperglycemia, which comprises administering to a patient of the disease attendant on hyperglycemia at least one of the above-specified monosaccharides in an effective dose.

In still a further aspect of this invention, there is also provided a preparation composition for depressing the rise in blood sugar due to carbohydrate ingestion, comprising, as an active ingredient, at least one of the above-specified monosaccharides, and pharmaceutical additives.

In yet still a further aspect of this invention, there is also provided a method of depressing the rise in blood sugar due to carbohydrate ingestion, which comprises administering at least one of the above-specified monosaccharides in an effective dose.

In yet still a further aspect of this invention, there is also provided a wholesome food for preventing obesity, comprising at least one of the above-specified monosaccharides in a proportion of at least 2 wt.% of other carbohydrates than those specified herein.

According to the present invention, it has been confirmed that L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose have an effective action to depress the rise in blood sugar for sucrose or starch loading.

The use of at least one of these compounds as an active ingredient makes it possible to provide, as a prophylactic and remedial preparation for diseases attendant on hyperglycemia, a prophylactic and remedial preparation free of any fear as to the safety for the living body, in particular, organs in which carbohydrate metabolism actively takes place, even when it is continuously used for a long period of time, and at the same time a wholesome food.

These and other objects and advantages of the present invention will become apparent from the preferred embodiments of this invention, which will be described subsequently in detail.

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

The monosaccharides useful in the practice of this invention are one or more compounds selected from the group consisting of L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose. Among these compounds, L-arabinose is particularly preferred.

These monosaccharides strongly inhibit the hydrolysis of sucrose and maltose, which is catalyzed by alpha -glucosidases derived from the small intestine. They also have an action to depress the rise in blood sugar due to carbohydrate ingestion. These monosaccharides occur in nature and are substantially innocuous because they have not been reported to be poisonous to human beings and animals. In particular, L-arabinose is known to be hard to be taken up from the digestive tract and is considered to have no systemic influence.

No particular limitation is imposed on the additives incorporated into the prophylactic and remedial preparation composition for diseases attendant on hyperglycemia and the preparation composition for depressing the rise in blood sugar according to the present invention (hereinafter referred to as the "inventive compositions") so long as they are additives generally used in pharmaceutical preparations. As examples thereof, may be mentioned excipients, stabilizers, preservatives, binders, disintegrators and the like. Sucrose may be used as an edulcorant upon the formulation of these compositions. However, a low-caloric edulcorant such as aspartame or stevioside may be used. Examples of the form of the inventive compositions include a solution, capsule, granule, pill, powder and tablet. The inventive compositions or preparations may be administered either orally or enterally.

At least one of the above-specified monosaccharides or the inventive compositions may be suitably added to foods to provide wholesome foods for preventing and remedying diseases attendant on hyperglycemia, and preventing the rise in blood sugar due to carbohydrate ingestion and obesity. In the case where such a wholesome food is produced, the monosaccharide according to this invention may preferably be added in a proportion of 2.0 wt.% of other carbohydrates than those specified herein. Any proportions not lower than 2.0 wt.% permits sufficient depression of the rise in blood sugar due to carbohydrate ingestion. However, it is particularly preferred to add such a compound in a proportion of

2.0-50 wt.% of the other carbohydrates.

The dosing method and dose of the specified monosaccharide to a human being should be determined according to the age, weight and condition of the patient to be dosed. In many cases, however, the monosaccharide is preferably dosed in portions in a range of 0.5-3 g/day before each meal or during the meal.

EXAMPLES

The present invention will hereinafter be described in more detail by the following examples. However, it should be borne in mind that this invention is not limited to and by these examples only.

Example 1:

(Action to inhibit the hydrolytic activity of homogenate prepared from rabbit small intestine mucous membrane to carbohydrate)

A native kind of white rabbits (weight: 3.0-3.5 kg) were sacrificed by exsanguination to take out their small intestines.

After freezing and thawing the small intestines thus taken out, they were homogenized in a 5 mM EDTA buffer (pH: 7.0) and subjected to centrifugation for 60 minutes at 60,000 x g. Precipitate thus formed was collected and suspended again in a 10 mM potassium phosphate buffer (pH: 7.0), thereby obtaining a crude enzyme suspension.

Sucrose (20 mM) and maltose (20 mM) were used as substrates.

Each reaction mixture was formulated so as to contain 350 microliters of a 100 mM maleate buffer (pH: 6.8), 100 microliters of a substrate solution, 50 microliters of the crude enzyme suspension and 50 microliters of a test solution. Substances to be tested were separately dissolved in a maleate buffer (pH: 6.8) before use.

Respective reactions were conducted for 15 minutes at 37 DEG C. The amounts of glucose formed were determined by the glucose oxidase method and are shown in Tables 1-3.

As shown in Table 1, L-arabinose, D-xylose and D-ribose among the pentoses about which the inhibiting action had been investigated had strong sucrase-inhibiting action and maltase-inhibiting action, and L-xylose, D-xylulose, D-ribulose and D-lyxose exhibited inhibiting actions second to these.

However, no or little inhibiting action was recognized as to D-arabinose, L-lyxose and L-xylulose.

With respect to the hexoses, strong sucrase-inhibiting action and maltase-inhibiting action were recognized on 2-deoxy-D-galactose, D-tagatose and L-fucose. However, L-sorbose, D-fucose, D-talose, D-mannose, D-galactose and D-galactosamine showed no or little inhibiting action (Table 2).

With respect to the oligosaccharides, those having an effective inhibiting action on these enzymes were not found from the substances investigated (Table 3).

Example 2:

(Action to depress the rise in blood sugar after carbohydrate loading)

ICR male mice (weight 30-35 g) were used in proportions of 5 mice per group.

After causing the mice to fast, sucrose or starch was orally administered in a proportion of 1 g/kg to the mice of each group, and at the same time substances to be tested were orally given to mice of their corresponding groups.

Blood was collected from the retroorbital sinus of each mouse before carbohydrate loading and upon elapsed times of 30 minutes, 60 minutes and 120 minutes after the loading to determine the concentration of glucose in the blood plasma by the glucose oxidase method.

As shown in Table 4, it was confirmed that the rise in blood sugar due to sucrose loading is depressed in dependence on the dose by L-arabinose and D-xylose (each orally administered in proportions of 25, 50 and 100 mg/kg), and moreover significantly depressed by D-tagatose, 2-deoxy-D-galactose, L-fucose, L-xylose, D-ribose, D-ribulose, D-lyxose, D-xylulose (each orally administered in a proportion of 100 mg/kg).

Further, L-arabinose exhibited a depressing action on the rise in blood sugar due to starch loading in dependence on the dose.

Example 3:

(Action to depress increase in body weight of mice)

ICR male mice after the elapse of 5 weeks from their birth were used in proportions of 10 mice per group.

After the mice were preliminarily bred for 1 week with a commercially-available ordinary feed ("Mouse-Rat Feed MF", product of Oriental Yeast Co., Ltd.), fully nutritious feeds to which L-arabinose had been added in proportions of 0.5% (Group 1), 1.0% (Group 2) and 2.0% (Group 3) (ordered products in the form of pellets, each making use, as a base, of a feed obtained by substituting 30% of the carbohydrate contained in an "Oriental Mixed Mouse-Rat Feed" produced by the same company as above with granulated sugar) were freely ingested to the mice of the respective groups.

Mice of a control group were caused to freely ingest the same feed as those used in the run groups except that L-arabinose was not added.

The mice of each group were separately weighed after 10 days, 20 days, 30 days and 60 days from the beginning of the ingestion to determine their weight increases from the initial weights, thereby calculating an average value of the weights increased in each group. The amounts of the feeds and water ingested were also determined.

During the experiment, the laboratory animals showed no abnormality in general medical condition and behavior, and had no death at all.

As shown in Table 5, the mice of the groups in which L-arabinose was added to their feeds showed less weight increases compared with the mice of the control group. This effect was dependent on the amount of L-arabinose added.

Any significant differences were not recognized as to the amounts of the feeds and water ingested.

Data supplied from the esp@cenet database - I2

Online European Patent Register - Results

Status of the database as of 12-09-2003 (dd-mm-yyyy)

Choose your View: All data mentioned in Rule 92 and EPIDOS



[Return to Search Screen](#)

Most recent event

No opposition filed within
time limit

Date of publication 01-07-1998 [1998/27]

Publication numbers, publication type and publication dates

EP0560284 A1 15-09-1993 [1993/37]

EP0560284 B1 09-07-1997 [1997/28]

Date of grant 09-07-1997 [1997/28]

Application numbers and filing date

EP19930103763 (93103763.4)

Date of filing 09-03-1993 [1993/37]

Date of publication of search report

Date of publication of
search report 15-09-1993 [1993/37]

Priority number, priority date

JP19920086196 10-03-1992;

JP19920355368 21-12-1992 [1993/37]

Classification (IPC) and bulletin number

A61K31/70 [1993/37]

Designated states

AT , BE , CH , DE , FR , GB , IT , LI , NL [1993/37]

English title

Prophylactic and remedial preparation for diseases attendant on
hyperglycemia, and wholesome food [1993/37]

French title

Préparation prophylactique et thérapeutique pour maladies dépendant de
l'hyperglycémie et aliment soin [1993/37]

German title

Therapeutische und Vorbeugungszusammensetzung für hyperglykämie-
abhängige Erkrankungen und Gesundheitsnahrung [1997/28]

Designated states, applicant name, address

FOR ALL DESIGNATED STATES

Godo Shusei Co., Ltd.

2-10, 6-chome, Ginza, Chuo-ku

Tokyo/Japan/JP [1993/37]

Inventor name, address

01 / Seri, Kenji / 1567-5-502, Hachijou / Yashio-shi, Saitama / JP

02 / Sanai, Kazuko / 5-14-10-607, Sagamigaoka / Zama-shi, Kanagawa / JP

03 / Negishi, Shigenori / 470-3-204, Hikawacho / Soka-shi, Saitama / JP

04 / Akino, Toshiro / 470-2-402, Hikawacho / Soka-shi, Saitama / JP

[1993/37]

Representative name, address

Wächtershäuser, Günter, Prof. Dr.

Patentanwalt, Tal 29

80331 München/DE [1993/37]

Filing language

EN

Procedure language

EN

Publication language

B1 EN [1997/28]

A1 EN [1993/37]

Location of file and fax number for file inspection requests

Application is treated in

(/fax-nr) MUNICH/(+49-89) 23994465

Examination procedure

request for examination 15-03-1994 [1994/19]

Examination report(s) A.96(2), R.51(2)

date dispatch/time-
limit/reply 19-10-1995/M06/29-04-1996
14-12-1994/M06/26-06-1995

communication R.51(4)
dispatched 29-10-1996
- approval (yes or no) no
- later approval 17-12-1996

communication R.51(6)
dispatched 09-01-1997
payment of fee for
grant/fee for printing 04-03-1997/04-03-1997

Opposition procedure

no opposition filed, time-
limit expired on 10-04-1998 [1998/27]

Renewal fees

Renewal fee A.86 (patent
year / paid) 03/30-03-1995
04/28-03-1996
05/27-03-1997

Documents cited in the European Search

US4745185 A [Y];
WO9109604 A [Y];
EP0456948 A [Y];
JP63308001 A [Y]
[X] PROC.INT.UNION PHYSIOL.SCI. vol. 7, no. 24, 1968, page 405
'Insulin Secretion as the Cause of Hypoglycemia Produced by
Infusion of D-Ribose in the Rabbit';
[X] ENDOCRINOL.JPN. vol. 25, no. 2, 1978, pages 163 - 9
'Sustained Hypoglycemia in Response to Intravenous Infusion
of D-Ribose in Normal Dogs';
[X] DIABETES vol. 19, no. 1, 1970, pages 23 - 7 'Hormonal Changes
during Ribose-Induced Hypoglycemia';
[X] ACTA ENDOCR. (SUPPL. 138) 1969, 'Mechanism of Ribose Induced
Hypoglycemia';
[X] BOLL.SOC.ITAL.BIOL.SPER. vol. 41, no. 5, 1965, pages 260 -
265 'Indagini sul metabolismo dello xilosio nell'uomo - VI /
V';
[Y] PATENT ABSTRACTS OF JAPAN vol. 131, no. 51 (C-584)12 April
1989 & JP-A-63 308 001 (RIIDE CHEM.KK)
[End of Data]

Return to Search Screen
16-09-2003 13:44:10